Transcriptional control of cellular metabolism by mtor signaling

Cancer Research

Volumn 71, Issue 8, 2011, Pages 2815-2820

  Yecies, Jessica L ^a   Manning, Brendan D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3; GUANOSINE TRIPHOSPHATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; PENTOSE PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; ENDOPLASMIC RETICULUM; GENE EXPRESSION; GLYCOLYSIS; HYPOXIA; LIPOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUBEROUS SCLEROSIS; TUMOR CELL;

ANIMALS; HUMANS; PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 79954576972     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4158     Document Type: Review

References (42)

1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324:1029-33.
2. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39:171-83.
3. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
4. Huang J, Manning BD. The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J 2008;412:179-90. (Pubitemid 351758225)
5. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008;27(Suppl 2):S43-51.
6. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
7. Mayer C, Grummt I. Ribosome biogenesis and cell growth: MTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 2006;25:6384-91. (Pubitemid 44582283)
8. Neufeld TP. TOR-dependent control of autophagy: Biting the hand that feeds. Curr Opin Cell Biol 2010;22:157-68.
9. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: Sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007;12:108-13. (Pubitemid 47199124)
10. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 2007;41:401-27.
11. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601. (Pubitemid 38796850)
12. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005;24:6465-81. (Pubitemid 41486630)
13. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32. (Pubitemid 37328811)
14. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF- 1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004. (Pubitemid 32476461)
15. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7. (Pubitemid 43050086)
16. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, et al. mTOR and HIF-1a-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A 2009;106:11137-42.
17. West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998;17:769-80. (Pubitemid 28412498)
18. Demoulin JB, Ericsson J, Kallin A, Rorsman C, Rönnstrand L, Heldin CH. Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J Biol Chem 2004;279:35392-402. (Pubitemid 39100539)
19. Zhou RH, Yao M, Lee TS, Zhu Y, Martins-Green M, Shyy JY. Vascular endothelial growth factor activation of sterol regulatory element binding protein: A potential role in angiogenesis. Circ Res 2004;95: 471-8. (Pubitemid 39180927)
20. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, et al. Control of lipid metabolism by phosphorylationdependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 2005;1:379-91. (Pubitemid 43960622)
21. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Aktdependent cell growth. Cell Metab 2008;8:224-36.
22. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: MTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010;107: 3441-6.
23. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003;100:12027-32. (Pubitemid 37271509)
24. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev 2000;14:2712-24. (Pubitemid 32531198)
25. Du X, Kristiana I, Wong J, Brown AJ. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: A link between a key cell proliferative pathway and membrane synthesis. Mol Biol Cell 2006;17:2735-45. (Pubitemid 43825509)
26. Werstuck GH, Lentz SR, Dayal S, Hossain GS, Sood SK, Shi YY, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001;107:1263-73. (Pubitemid 32494543)
27. Lee JN, Ye J. Proteolytic activation of sterol regulatory elementbinding protein induced by cellular stress through depletion of Insig-1. J Biol Chem 2004;279:45257-65. (Pubitemid 39430941)
28. Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009;119:1201-15.
29. Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008;29:541-51. (Pubitemid 351384644)
30. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77. (Pubitemid 47469806)
31. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: New players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65. (Pubitemid 44101970)
32. Menendez JA, Lupu R. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: A new family of anticancer agents?Curr Pharm Biotechnol 2006;7: 495-502.
33. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009;324:1076-80.
34. Kuo W, Lin J, Tang TK. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer 2000;85:857-64. (Pubitemid 30131478)
35. Roy D, Liehr JG. Characterization of drug metabolism enzymes in estrogen-induced kidney tumors in male Syrian hamsters. Cancer Res 1988;48:5726-9.
36. Simile M, Pascale RM, De Miglio MR, Nufris A, Daino L, Seddaiu MA, et al. Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. Int J Cancer 1995;62:210-5.
37. Bokun R, Bakotin J, Milasinović DD. Semiquantitative cytochemical estimation of glucose-6-phosphate dehydrogenase activity in benign diseases and carcinoma of the breast. Acta Cytol 1987;31:249-52. (Pubitemid 17086100)
38. Hughes EC. The effect of enzymes upon metabolism, storage, and release of carbohydrates in normal and abnormal endometria. Cancer 1976;38[1 Suppl]:487-502.
39. Du̧tu R, Nedelea M, Veluda G, Burculȩt V. Cytoenzymologic investigations on carcinomas of the cervix uteri. Acta Cytol 1980;24: 160-6. (Pubitemid 10074609)
40. Zampella EJ, Bradley EL Jr, Pretlow TG 2nd. Glucose-6-phosphate dehydrogenase: A possible clinical indicator for prostatic carcinoma. Cancer 1982;49:384-7. (Pubitemid 12211858)
41. Dessì S, Batetta B, Cherchi R, Onnis R, Pisano M, Pani P. Hexose monophosphate shunt enzymes in lung tumors from normal and glucose-6-phosphate- dehydrogenase-deficient subjects. Oncology 1988;45:287-91.
42. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009;2:pe24.